Dronedarone a new drug for atrial fibrillation or atrial flutter

LV Juan-li; LIU Yang; Li Yan; Liu Zhen-hua

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 29 Issue 1

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2011 > 29(1): 41-44

LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.

Citation:

LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.

Dronedarone a new drug for atrial fibrillation or atrial flutter

General Hospital of Chinese People's Armed Police Forces, Beijing 100039, China

Received Date: 2010-03-04
Rev Recd Date: 2010-03-11

Abstract

Dronedarone is analogues as amiodarone, the structure is not iodine, reducing iodine-induced organ toxicity, is one of the new anti-arrhythmia drugs. on July 1, 2009 , It has been approved by FDA for the treatment of atrial fibrillation or atrial flutter in patients with heart disease. In this paper, after a literature search for Dronedarone with key words, the pharmacological , pharmacokinetics, clinical evaluation, drug interactions and adverse reactions of dronedarone are reviewed.
- dronedarone,
- atrial fibrillation,
- atrial flutter,
- anti-arrhythmia drugs

References

[1]	Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States.1980~1998[J]. Am J Epidemiol,2002,155(9):819.
[2]	Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization foratrial fibrillation in the United States, 1985 through 1999: implications for primary prevention[J]. Circulation ,2003,108(6):711.
[3]	Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial[J]. Lancet,2000, 356(9244):1789.
[4]	Wyse DG, Waldo AL, DiMarco JP,et al.Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation[J]. N Engl J Med, 2002,347(23):1825 .
[5]	Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects[J]. J Cardiovasc Electrophysiol.2006, 17(12):S17.
[6]	Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone[J]. Circulation, 1999,100(22):2276 .
[7]	Hodeige D, Heyndrickx JP, Chatelain P, et al. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs[J]. Eur J Pharmacol,1995,279(1):25.
[8]	Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxide in amiodarone and dronedarone-induced coronary vasodilatation in guinea pig heart[J].Eur J Pharmacol ,2004,496(1-3):119.
[9]	Celestino D, Medei E, Moro S,et al. Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study[J]. J. Cardiovasc Pharmacol Ther,2007, 12(3): 248.
[10]	Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone[J]. J Cardiovasc Pharmacol, 2002,39(5):677.
[11]	Varró A, Takács J, Németh M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone[J]. Br J Pharmacol,2001,133(5):625.
[12]	Chatelain P, Meysmans L, Mateazzi Jr, et al. Clinietm: Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β-adrenoceptor and adenylate cyclase in rat heart[J]. Br J Pharmacol,1995 ,116(3):1949.
[13]	Pantos C, Mourouzis I, Delbruyere M, et al. Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and post ischemic performance of the isolated rat heart[J]. Eur J Pharmacol, 2002, 444(3):191.
[14]	Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study[J]. Eur Heart J ,2003, 24 (16): 1481
[15]	Singh BN, Connolly SJ, Crijns HJ,et al.EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[J]. N Engl J Med, 2007,357(10): 987.
[16]	Davy JM, Herold M, Hoglund C, et al. ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study[J]. Am. Heart J,2008,156(3):527.
[17]	KΦber L , TorpPedersen C , McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure[J]. N Engl J Med ,2008 ,358 (25) :2678.
[18]	Hohnloser SH, Crijns HJ, van Eickels M,et al.ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation[J]. N Engl J Med ,2009,360(7): 668.
[19]	Sanofi-Aventis. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone [EB/OL]. (2008-12-23) http://en.sanofi-aventis.com/binaries/20081223_dionysos_fe_en_en_tcm28-23624.pdf.
[20]	Dale KM, White CM.Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter[J]. Ann Pharmacother,2007,41(4):599.
[21]	Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials[J]. Am J Cardiol ,2003, 91(6A):15D.
[22]	Patel PD, Bhuriya R, Patel DD,et al. Dronedarone for atrial fibrillation: a new therapeutic agent[J]. Vasc Health Risk Manag,2009,5:635.
[23]	Quaglino D, Ha HR, Duner E, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol Lung Cell Mol Physiol, 2004,287(2):L438.
[24]	Van Beeren HC, Jong WM, Kaptein E,et al. Dronedarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence[J]. Endocrinology ,2003,144(2):552.
[25]	Zipes DP, Camm AJ, Borggrefe M,et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines[J]. Circulation. 2006 ,114(10):e385.
[26]	Tschuppert Y,Buclin T,Rothuizen LE,et al. Effect of dronedarone on renal function in healthy subjects[J].Br J Clin Pharmacol,2007,64(6): 785.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2384) PDF downloads(110) Cited by()

Proportional views

Dronedarone a new drug for atrial fibrillation or atrial flutter

General Hospital of Chinese People's Armed Police Forces, Beijing 100039, China

Received Date: 2010-03-04

Rev Recd Date: 2010-03-11

Key words:

Abstract: Dronedarone is analogues as amiodarone, the structure is not iodine, reducing iodine-induced organ toxicity, is one of the new anti-arrhythmia drugs. on July 1, 2009 , It has been approved by FDA for the treatment of atrial fibrillation or atrial flutter in patients with heart disease. In this paper, after a literature search for Dronedarone with key words, the pharmacological , pharmacokinetics, clinical evaluation, drug interactions and adverse reactions of dronedarone are reviewed.

HTML

Reference (26)

[1]	Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States.1980~1998[J]. Am J Epidemiol,2002,155(9):819.
[2]	Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization foratrial fibrillation in the United States, 1985 through 1999: implications for primary prevention[J]. Circulation ,2003,108(6):711.
[3]	Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial[J]. Lancet,2000, 356(9244):1789.
[4]	Wyse DG, Waldo AL, DiMarco JP,et al.Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation[J]. N Engl J Med, 2002,347(23):1825 .
[5]	Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects[J]. J Cardiovasc Electrophysiol.2006, 17(12):S17.
[6]	Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone[J]. Circulation, 1999,100(22):2276 .
[7]	Hodeige D, Heyndrickx JP, Chatelain P, et al. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs[J]. Eur J Pharmacol,1995,279(1):25.
[8]	Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxide in amiodarone and dronedarone-induced coronary vasodilatation in guinea pig heart[J].Eur J Pharmacol ,2004,496(1-3):119.
[9]	Celestino D, Medei E, Moro S,et al. Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study[J]. J. Cardiovasc Pharmacol Ther,2007, 12(3): 248.
[10]	Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone[J]. J Cardiovasc Pharmacol, 2002,39(5):677.
[11]	Varró A, Takács J, Németh M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone[J]. Br J Pharmacol,2001,133(5):625.
[12]	Chatelain P, Meysmans L, Mateazzi Jr, et al. Clinietm: Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β-adrenoceptor and adenylate cyclase in rat heart[J]. Br J Pharmacol,1995 ,116(3):1949.
[13]	Pantos C, Mourouzis I, Delbruyere M, et al. Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and post ischemic performance of the isolated rat heart[J]. Eur J Pharmacol, 2002, 444(3):191.
[14]	Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study[J]. Eur Heart J ,2003, 24 (16): 1481
[15]	Singh BN, Connolly SJ, Crijns HJ,et al.EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[J]. N Engl J Med, 2007,357(10): 987.
[16]	Davy JM, Herold M, Hoglund C, et al. ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study[J]. Am. Heart J,2008,156(3):527.
[17]	KΦber L , TorpPedersen C , McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure[J]. N Engl J Med ,2008 ,358 (25) :2678.
[18]	Hohnloser SH, Crijns HJ, van Eickels M,et al.ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation[J]. N Engl J Med ,2009,360(7): 668.
[19]	Sanofi-Aventis. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone [EB/OL]. (2008-12-23) http://en.sanofi-aventis.com/binaries/20081223_dionysos_fe_en_en_tcm28-23624.pdf.
[20]	Dale KM, White CM.Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter[J]. Ann Pharmacother,2007,41(4):599.
[21]	Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials[J]. Am J Cardiol ,2003, 91(6A):15D.
[22]	Patel PD, Bhuriya R, Patel DD,et al. Dronedarone for atrial fibrillation: a new therapeutic agent[J]. Vasc Health Risk Manag,2009,5:635.
[23]	Quaglino D, Ha HR, Duner E, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol Lung Cell Mol Physiol, 2004,287(2):L438.
[24]	Van Beeren HC, Jong WM, Kaptein E,et al. Dronedarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence[J]. Endocrinology ,2003,144(2):552.
[25]	Zipes DP, Camm AJ, Borggrefe M,et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines[J]. Circulation. 2006 ,114(10):e385.
[26]	Tschuppert Y,Buclin T,Rothuizen LE,et al. Effect of dronedarone on renal function in healthy subjects[J].Br J Clin Pharmacol,2007,64(6): 785.

Message Board

Dronedarone a new drug for atrial fibrillation or atrial flutter

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views